RxDoctor Payments Data

Robert Schnackenberg, MD

Psychiatry · Columbia, SCNPI 1548240484

Payments from drug & device makers

$5,698in general payments, 2019–2025

Across 353 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$674
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$651
  • Otsuka America Pharmaceutical, Inc.$464
  • Bausch Health US, LLC$443
  • Lundbeck LLC$426
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,64999%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,698 in reported general payments places this provider in the 85th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$55,590
Medicare patients
74
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl11$30,036
TrintellixVortioxetine Hydrobromide21$23,718
AmbienZolpidem Tartrate13$15,805
BelsomraSuvorexant13$5,551
Duloxetine Hcl98$2,391
Lisdexamfetamine Dimesylate11$2,349
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine80$2,208
Lamotrigine127$2,129
Aripiprazole41$2,049
Clozapine OdtClozapine13$1,962
Modafinil46$1,885
Mirtazapine105$1,761
Ziprasidone Hcl49$1,710
Alprazolam201$1,666
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine28$1,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,015$30,03611 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$54$23,71821 claims
Almatica Pharma LLCSertraline Hcl$94$87260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →